Vericel (NASDAQ:VCEL) Coverage Initiated by Analysts at TD Cowen

TD Cowen began coverage on shares of Vericel (NASDAQ:VCELFree Report) in a research note issued to investors on Thursday morning, Marketbeat.com reports. The firm issued a buy rating and a $55.00 target price on the biotechnology company’s stock.

A number of other research analysts have also recently commented on VCEL. HC Wainwright increased their price target on Vericel from $53.00 to $55.00 and gave the company a buy rating in a research note on Thursday, May 9th. StockNews.com cut shares of Vericel from a hold rating to a sell rating in a research report on Thursday, June 6th. Finally, Truist Financial reissued a buy rating and set a $54.00 price objective on shares of Vericel in a research report on Tuesday, March 26th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of Moderate Buy and a consensus target price of $48.17.

Get Our Latest Stock Analysis on VCEL

Vericel Price Performance

Shares of Vericel stock opened at $45.00 on Thursday. The stock’s 50-day moving average is $46.59 and its 200-day moving average is $44.22. The firm has a market cap of $2.19 billion, a price-to-earnings ratio of -4,495.50 and a beta of 1.74. Vericel has a one year low of $30.18 and a one year high of $53.05.

Vericel (NASDAQ:VCELGet Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03. The business had revenue of $51.28 million during the quarter, compared to analysts’ expectations of $49.07 million. Vericel had a return on equity of 0.21% and a net margin of 0.22%. The firm’s revenue for the quarter was up 25.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.16) earnings per share. On average, equities analysts expect that Vericel will post 0.09 EPS for the current year.

Insider Activity

In related news, CEO Dominick Colangelo sold 17,500 shares of the company’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $44.12, for a total transaction of $772,100.00. Following the completion of the sale, the chief executive officer now directly owns 220,752 shares in the company, valued at approximately $9,739,578.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CEO Dominick Colangelo sold 17,500 shares of the stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $44.12, for a total value of $772,100.00. Following the completion of the transaction, the chief executive officer now directly owns 220,752 shares of the company’s stock, valued at $9,739,578.24. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Robert L. Md Zerbe sold 3,278 shares of the stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $51.57, for a total transaction of $169,046.46. Following the completion of the transaction, the director now directly owns 23,395 shares of the company’s stock, valued at $1,206,480.15. The disclosure for this sale can be found here. Insiders sold 38,278 shares of company stock worth $1,721,471 in the last three months. Corporate insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Vericel

A number of institutional investors have recently made changes to their positions in VCEL. Vanguard Group Inc. boosted its holdings in Vericel by 1.2% in the first quarter. Vanguard Group Inc. now owns 3,413,442 shares of the biotechnology company’s stock worth $177,567,000 after purchasing an additional 39,349 shares during the last quarter. Conestoga Capital Advisors LLC boosted its stake in shares of Vericel by 4.9% during the 4th quarter. Conestoga Capital Advisors LLC now owns 2,339,960 shares of the biotechnology company’s stock worth $83,326,000 after acquiring an additional 109,215 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Vericel by 10.9% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,021,695 shares of the biotechnology company’s stock worth $53,149,000 after acquiring an additional 100,797 shares during the last quarter. William Blair Investment Management LLC boosted its stake in shares of Vericel by 0.8% during the 1st quarter. William Blair Investment Management LLC now owns 841,677 shares of the biotechnology company’s stock worth $43,784,000 after acquiring an additional 6,792 shares during the last quarter. Finally, Congress Asset Management Co. MA raised its position in shares of Vericel by 509.1% during the 1st quarter. Congress Asset Management Co. MA now owns 836,481 shares of the biotechnology company’s stock valued at $43,514,000 after purchasing an additional 699,147 shares during the period.

Vericel Company Profile

(Get Free Report)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

Recommended Stories

Analyst Recommendations for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.